Ocera Therapeutics Inc (OCRX) 7.64 $OCRX
Ocera Reports First Quarter Financial Results
GlobeNewswire - Thu May 08, 3:49PM CDT
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a biopharmaceutical company focused on innovative therapeutics for orphan liver disease, announced today its financial results for the first quarter ended March 31, 2014. Net loss for the period was $4.1 million, including net loss from continuing operations of $5.2 million offset by a $1.1 million net income from discontinued operations, compared to a net loss of $0.7 million in the same period of 2013. As of March 31, 2013, Ocera had cash, cash equivalents and investments of $43.1 million.
Ocera Therapeutics Announces Appointment of Gaurav Aggarwal, M.D., as Chief Business Officer
GlobeNewswire - Fri May 02, 3:05PM CDT
Ocera Therapeutics (Nasdaq:OCRX) today announced that Gaurav Aggarwal, M.D., has joined the Company as its Chief Business Officer.
Global Diarrhea Therapeutics Pipeline Review 2014
M2 - Tue Apr 29, 8:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/63vt65/diarrhea) has announced the addition of the "Diarrhea - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diarrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diarrhea and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Diarrhea - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diarrhea and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diarrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Diarrhea pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Ipsen S.A. - A. Menarini Industrie Farmaceutiche Riunite Srl - Shire Plc - Mucosis B.V. - Helsinn Healthcare S.A. - Ventria Bioscience - Ache Laboratorios Farmaceuticos S/A - Ocera Therapeutics, Inc. - GP Pharm, S.A. - Tioga Pharmaceuticals, Inc. - Intercept Pharmaceuticals, Inc. - Aegis Therapeutics, LLC - Drais Pharmaceuticals, Inc. - DesignMedix, Inc. - Chongqing Zhifei Biological Products Co., Ltd. - Rottapharm|Madaus - Sanofi Pasteur SA - Inhibikase Therapeutics, Inc. - Rebiotix Inc. For more information visit http://www.researchandmarkets.com/research/63vt65/diarrhea
Ocera Therapeutics to Announce First Quarter Financial Results
GlobeNewswire - Tue Apr 29, 7:00AM CDT
Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it will release its first quarter financial results on May 8, 2014 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day. A replay of the call will be available for one month following the event.
Nasdaq stocks posting largest percentage decreases
AP - Mon Mar 31, 6:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Ocera Reports Fourth Quarter and Year-End 2013 Financial Results
GlobeNewswire - Thu Mar 13, 3:30PM CDT
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a biopharmaceutical company focused on innovative therapeutics for orphan liver disease, announced today its financial results and other information for the fourth quarter and year ended December 31, 2013. Revenues from continuing operations for the fourth quarter were $0.1 million compared to no revenue for the same period in 2012. Net loss for the fourth quarter from continuing operations was $6.6 million and $0.7 million from discontinued operations, compared to a net loss of $0.7 million in the same period of 2012. As of December 31, 2013, Ocera had cash, cash equivalents and investments of $47.2 million.
3 Stocks Rising on Big Volume
at The Street - Thu Mar 06, 5:00AM CST
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Ocera Therapeutics to Announce Fourth Quarter and Year End Financial Results
GlobeNewswire - Mon Mar 03, 11:02PM CST
Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it will release its fourth quarter financial results on March 13, 2014 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day. A replay of the call will be available for one week following the event.
Ocera Therapeutics to Present at the Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Wed Feb 26, 3:09PM CST
Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, announced today that company management plans to present at the Cowen Health Care Conference. Ocera's presentation is scheduled for Wednesday, March 5, 2014 at 8:00 AM ET.
5 Stocks Ready to Skyrocket Higher
at The Street - Wed Feb 19, 1:14PM CST
These stocks are setting up to explode to the upside.
Why Ocera (OCRX) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 23, 7:37AM CST
Ocera could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision front
Ocera Therapeutics enrols first patient in Phase IIb Study of OCR-002 for treatment of acute hepatic encephalopathy
M2 - Thu Jan 09, 5:35AM CST
Biopharmaceutical company Ocera Therapeutics (NasdaqGM:OCRX) revealed on Wednesday the admission of the first patient in its multi-centre Phase 2b study, the 'STOP-HE' or OCR002-HE209 trial.
Ocera Therapeutics Announces Enrollment of the First Patient in a Phase IIb Study for Treatment of Acute Hepatic Encephalopathy
GlobeNewswire - Wed Jan 08, 2:59PM CST
Ocera Therapeutics (Nasdaq:OCRX) today announced enrollment of the first patient in its multi-center Phase 2b study, the "STOP-HE" or OCR002-HE209 trial. This study is evaluating the efficacy, safety and pharmacokinetics of OCR-002, or ornithine phenylacetate, in hospitalized patients with liver cirrhosis and an acute episode of hepatic encephalopathy (HE). HE is a serious complication of liver failure and decompensated cirrhosis in the setting of chronic liver disease, where elevation of ammonia concentration in the blood and brain can lead to deterioration of neurocognitive function, ranging from subtle abnormalities to frank (overt) disorientation, stupor, coma and death. OCR-002 is a novel molecule, an ammonia scavenger which is intended to rapidly reduce the concentration of ammonia in the blood when administered as a continuous intravenous infusion. OCR-002 has been granted orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant HE in patients with acute liver failure or acute on chronic liver disease.
Ocera Therapeutics Announces Election of Wendell Wierenga to Board
GlobeNewswire - Tue Dec 24, 12:00PM CST
Ocera Therapeutics (Nasdaq:OCRX) today announced that Wendell Wierenga, Ph.D., has joined its board of directors.
Ocera Therapeutics and the Roche Group Enter Into Technology Transfer and License Agreement
GlobeNewswire - Tue Dec 17, 3:00PM CST
Ocera Therapeutics (Nasdaq:OCRX) today announced that it has entered into a Technology Transfer and License Agreement with the Roche Group, including the Research and Early Development arms of both Genentech and Roche, for rights to its Macrocyclic Template Chemistry (MATCH(TM)) discovery platform. Under the terms of the agreement, Ocera will transfer ownership of equipment and materials related to the use of the MATCH(TM) technology, and grant a license to Genentech and Roche under Ocera's related intellectual property rights. The Roche Group will make a one-time payment to Ocera of $4 million.
Ocera Therapeutics Announces Staffing Transition
GlobeNewswire - Wed Dec 11, 3:00PM CST
Ocera Therapeutics (Nasdaq:OCRX) today announced that David S. Moore, its chief business officer, will be leaving Ocera to pursue other opportunities. Mr. Moore was a former member of the management team at Tranzyme and continued his employment with Ocera following the merger of Ocera and Tranzyme, which closed in July 2013. "We are grateful to David for his leadership in overseeing several aspects of our post-merger integration and streamlining," said Linda Grais, M.D., chief executive officer of Ocera. "We wish him the best in his future endeavors."
Ocera Therapeutics to Present at Piper Jaffrey Healthcare Conference
GlobeNewswire - Tue Nov 26, 3:00PM CST
Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., president and chief executive officer, plans to present at the 25 Annual Piper Jaffrey Healthcare Conference taking place at the New York Palace Hotel in New York City. Ocera's presentation is scheduled for Tuesday, December 3, 2013 at 04:10 PM ET. A live audio webcast of the presentation will be available in the "Investors" section of Ocera's website, www.ocerainc.com.
Ocera Reports Third Quarter Business Update and Financial Results
GlobeNewswire - Wed Nov 13, 4:00PM CST
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a biopharmaceutical company focused on innovative therapeutics for orphan liver disease, announced today financial results for the three and nine months ended September 30, 2013.
Ocera Reports First Quarter Financial Results
GlobeNewswire - Thu May 08, 3:49PM CDT
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a biopharmaceutical company focused on innovative therapeutics for orphan liver disease, announced today its financial results for the first quarter ended March 31, 2014. Net loss for the period was $4.1 million, including net loss from continuing operations of $5.2 million offset by a $1.1 million net income from discontinued operations, compared to a net loss of $0.7 million in the same period of 2013. As of March 31, 2013, Ocera had cash, cash equivalents and investments of $43.1 million.
Ocera Therapeutics Announces Appointment of Gaurav Aggarwal, M.D., as Chief Business Officer
GlobeNewswire - Fri May 02, 3:05PM CDT
Ocera Therapeutics (Nasdaq:OCRX) today announced that Gaurav Aggarwal, M.D., has joined the Company as its Chief Business Officer.
Global Diarrhea Therapeutics Pipeline Review 2014
M2 - Tue Apr 29, 8:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/63vt65/diarrhea) has announced the addition of the "Diarrhea - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diarrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diarrhea and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Diarrhea - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diarrhea and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diarrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Diarrhea pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Ipsen S.A. - A. Menarini Industrie Farmaceutiche Riunite Srl - Shire Plc - Mucosis B.V. - Helsinn Healthcare S.A. - Ventria Bioscience - Ache Laboratorios Farmaceuticos S/A - Ocera Therapeutics, Inc. - GP Pharm, S.A. - Tioga Pharmaceuticals, Inc. - Intercept Pharmaceuticals, Inc. - Aegis Therapeutics, LLC - Drais Pharmaceuticals, Inc. - DesignMedix, Inc. - Chongqing Zhifei Biological Products Co., Ltd. - Rottapharm|Madaus - Sanofi Pasteur SA - Inhibikase Therapeutics, Inc. - Rebiotix Inc. For more information visit http://www.researchandmarkets.com/research/63vt65/diarrhea
Ocera Therapeutics to Announce First Quarter Financial Results
GlobeNewswire - Tue Apr 29, 7:00AM CDT
Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it will release its first quarter financial results on May 8, 2014 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day. A replay of the call will be available for one month following the event.
Nasdaq stocks posting largest percentage decreases
AP - Mon Mar 31, 6:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Ocera Reports Fourth Quarter and Year-End 2013 Financial Results
GlobeNewswire - Thu Mar 13, 3:30PM CDT
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a biopharmaceutical company focused on innovative therapeutics for orphan liver disease, announced today its financial results and other information for the fourth quarter and year ended December 31, 2013. Revenues from continuing operations for the fourth quarter were $0.1 million compared to no revenue for the same period in 2012. Net loss for the fourth quarter from continuing operations was $6.6 million and $0.7 million from discontinued operations, compared to a net loss of $0.7 million in the same period of 2012. As of December 31, 2013, Ocera had cash, cash equivalents and investments of $47.2 million.
3 Stocks Rising on Big Volume
at The Street - Thu Mar 06, 5:00AM CST
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Ocera Therapeutics to Announce Fourth Quarter and Year End Financial Results
GlobeNewswire - Mon Mar 03, 11:02PM CST
Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it will release its fourth quarter financial results on March 13, 2014 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day. A replay of the call will be available for one week following the event.
Ocera Therapeutics to Present at the Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Wed Feb 26, 3:09PM CST
Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, announced today that company management plans to present at the Cowen Health Care Conference. Ocera's presentation is scheduled for Wednesday, March 5, 2014 at 8:00 AM ET.
5 Stocks Ready to Skyrocket Higher
at The Street - Wed Feb 19, 1:14PM CST
These stocks are setting up to explode to the upside.
Why Ocera (OCRX) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 23, 7:37AM CST
Ocera could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision front
Ocera Therapeutics enrols first patient in Phase IIb Study of OCR-002 for treatment of acute hepatic encephalopathy
M2 - Thu Jan 09, 5:35AM CST
Biopharmaceutical company Ocera Therapeutics (NasdaqGM:OCRX) revealed on Wednesday the admission of the first patient in its multi-centre Phase 2b study, the 'STOP-HE' or OCR002-HE209 trial.
Ocera Therapeutics Announces Enrollment of the First Patient in a Phase IIb Study for Treatment of Acute Hepatic Encephalopathy
GlobeNewswire - Wed Jan 08, 2:59PM CST
Ocera Therapeutics (Nasdaq:OCRX) today announced enrollment of the first patient in its multi-center Phase 2b study, the "STOP-HE" or OCR002-HE209 trial. This study is evaluating the efficacy, safety and pharmacokinetics of OCR-002, or ornithine phenylacetate, in hospitalized patients with liver cirrhosis and an acute episode of hepatic encephalopathy (HE). HE is a serious complication of liver failure and decompensated cirrhosis in the setting of chronic liver disease, where elevation of ammonia concentration in the blood and brain can lead to deterioration of neurocognitive function, ranging from subtle abnormalities to frank (overt) disorientation, stupor, coma and death. OCR-002 is a novel molecule, an ammonia scavenger which is intended to rapidly reduce the concentration of ammonia in the blood when administered as a continuous intravenous infusion. OCR-002 has been granted orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant HE in patients with acute liver failure or acute on chronic liver disease.
Ocera Therapeutics Announces Election of Wendell Wierenga to Board
GlobeNewswire - Tue Dec 24, 12:00PM CST
Ocera Therapeutics (Nasdaq:OCRX) today announced that Wendell Wierenga, Ph.D., has joined its board of directors.
Ocera Therapeutics and the Roche Group Enter Into Technology Transfer and License Agreement
GlobeNewswire - Tue Dec 17, 3:00PM CST
Ocera Therapeutics (Nasdaq:OCRX) today announced that it has entered into a Technology Transfer and License Agreement with the Roche Group, including the Research and Early Development arms of both Genentech and Roche, for rights to its Macrocyclic Template Chemistry (MATCH(TM)) discovery platform. Under the terms of the agreement, Ocera will transfer ownership of equipment and materials related to the use of the MATCH(TM) technology, and grant a license to Genentech and Roche under Ocera's related intellectual property rights. The Roche Group will make a one-time payment to Ocera of $4 million.
Ocera Therapeutics Announces Staffing Transition
GlobeNewswire - Wed Dec 11, 3:00PM CST
Ocera Therapeutics (Nasdaq:OCRX) today announced that David S. Moore, its chief business officer, will be leaving Ocera to pursue other opportunities. Mr. Moore was a former member of the management team at Tranzyme and continued his employment with Ocera following the merger of Ocera and Tranzyme, which closed in July 2013. "We are grateful to David for his leadership in overseeing several aspects of our post-merger integration and streamlining," said Linda Grais, M.D., chief executive officer of Ocera. "We wish him the best in his future endeavors."
Ocera Therapeutics to Present at Piper Jaffrey Healthcare Conference
GlobeNewswire - Tue Nov 26, 3:00PM CST
Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., president and chief executive officer, plans to present at the 25 Annual Piper Jaffrey Healthcare Conference taking place at the New York Palace Hotel in New York City. Ocera's presentation is scheduled for Tuesday, December 3, 2013 at 04:10 PM ET. A live audio webcast of the presentation will be available in the "Investors" section of Ocera's website, www.ocerainc.com.
Ocera Reports Third Quarter Business Update and Financial Results
GlobeNewswire - Wed Nov 13, 4:00PM CST
Ocera Therapeutics, Inc. (Nasdaq:OCRX), a biopharmaceutical company focused on innovative therapeutics for orphan liver disease, announced today financial results for the three and nine months ended September 30, 2013.
